Royalty Pharma PLC Form 4 insider transactions

Henry A. Fernandez, a director of Royalty Pharma plc, acquired 1,141 Class A Ordinary Shares on March 31, 2025, in lieu of a quarterly retainer payment.

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, acquired 300,000 Class A Ordinary Shares through an exchange of limited partnership interests.

Royalty Pharma plans to internalize its external manager and initiate a substantial share repurchase program, alongside reporting strong financial performance and portfolio growth.

Director Bonnie L. Bassler acquired 1,503 Class A Ordinary Shares of Royalty Pharma plc on December 31, 2024, in lieu of a $37,500 quarterly retainer payment.

Director Henry A. Fernandez acquired 1,503 Class A Ordinary Shares of Royalty Pharma plc on December 31, 2024, in lieu of a quarterly retainer payment.

Director Bonnie L. Bassler acquired 1,342 Class A Ordinary Shares of Royalty Pharma plc in lieu of a quarterly retainer payment.

Director Henry A. Fernandez acquired 1,342 Class A Ordinary Shares of Royalty Pharma plc in lieu of a quarterly retainer payment.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reports a charitable donation of ICAI Interests, which are exchangeable for Class A Ordinary Shares, according to a Form 4 filing.

EVP George W. Lloyd reports a charitable donation of RPI US LP Interests, which are exchangeable for Royalty Pharma plc Class A Ordinary Shares.

EVP Marshall Urist donates partnership interests exchangeable for Royalty Pharma shares to charity.

Director Henry A. Fernandez acquired 1,399 Class A Ordinary Shares of Royalty Pharma plc (RPRX) on June 28, 2024, in lieu of a quarterly retainer payment.

Director Bonnie L. Bassler acquired 1,399 Class A Ordinary Shares of Royalty Pharma plc in lieu of a quarterly retainer payment.

Director Gregory Norden reported acquiring 9,293 Class A Ordinary Shares of Royalty Pharma plc on June 7, 2024, through an award of restricted stock units.

Director Ted W. Love acquired 9,293 Class A Ordinary Shares of Royalty Pharma plc through a restricted stock unit award.

Director David C. Hodgson of Royalty Pharma plc reports the acquisition of 9,293 Class A Ordinary Shares through a restricted stock unit award.

Director Henry A. Fernandez reports the acquisition of 9,293 Class A Ordinary Shares of Royalty Pharma plc through a restricted stock unit award.

Catherine M. Engelbert, a director at Royalty Pharma plc, was granted 9,293 Class A Ordinary Shares on June 7, 2024, as part of the company's 2020 Independent Director Equity Incentive Plan.

Director Errol B. DeSouza reports acquisition of 9,293 Class A Ordinary Shares of Royalty Pharma plc through restricted stock units.

Director Bonnie L. Bassler of Royalty Pharma plc reports acquisition of 9,293 Class A Ordinary Shares through a restricted stock unit award.

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, acquired 300,000 Class A Ordinary Shares through an exchange of limited partnership interests.

Director Henry A. Fernandez acquired 1,240 Class A Ordinary Shares of Royalty Pharma plc in lieu of a quarterly retainer payment.

Bonnie L. Bassler, a director at Royalty Pharma plc, acquired 1,240 Class A Ordinary Shares on March 28, 2024, in lieu of a quarterly retainer payment.